Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?

Author(s): Johannes Hertelendy, Georg Reumuth, David Simons, Christian Stoppe, Bong-Sung Kim, Jan-Philipp Stromps, Paul C. Fuchs, Jurgen Bernhagen, Norbert Pallua, Gerrit Grieb*

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 5 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Macrophage migration inhibitory factor (MIF) was firstly described in the 1960s as a pleiotropic cytokine affecting a variety of immune cells. Different physiological functions mainly involving inflammatory reactions such as chemokine-like function and regulating systemic stress responses have been reported.

Objective: In several clinical studies the use of MIF as a biomarker has been investigated promising support for diseases with an inflammatory aspect such as sepsis, systemic infections and autoimmune diseases. This article in detail reviews clinical data and evaluates the function as biomarker focusing on inflammatory and autoimmune diseases.

Conclusion: Recent studies suggest MIF to be a marker for different inflammatory diseases and might serve as therapeutic target in the future.

Keywords: MIF, biomarker, infectious disease, autoimmune disease, cytokine, CD74, CXCR.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [601 - 605]
Pages: 5
DOI: 10.2174/0929867324666170714114200
Price: $65

Article Metrics

PDF: 71
HTML: 25
PRC: 2